Last scanned
Domain Age
Daily Visitors
Global Rank
Updated:
MCL and CLL/SLL Treatment | CALQUENCE® (acalabrutinib) 100 mg capsules | For HCPs
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
This website is hosted with Amazon.com, Inc., which reserves the following IP addresses for calquencehcp.com: 99.86.230.86, 99.86.230.89, 99.86.230.124, 99.86.230.129. Moreover, DNS used with this website include ns-1229.awsdns-25.org, ns-154.awsdns-19.com, ns-1775.awsdns-29.co.uk, ns-979.awsdns-58.net. Subnet identifier ranges from 99.86.0.0 to 99.86.255.255. Classless Inter-Domain Routing (CIDR) is 99.86.0.0/16. ARIN net type is Reallocated.
Last scanned
Domain Age
Daily Visitors
Global Rank
ns-1229.awsdns-25.org
ns-154.awsdns-19.com
ns-1775.awsdns-29.co.uk
ns-979.awsdns-58.net
{{value}}
2017-04-26
2024-04-26
CSC CORPORATE DOMAINS, INC.
{{value}}
The registrar of calquencehcp.com is CSC CORPORATE DOMAINS, INC. and the name expires on 2024-04-26. According to open source data, you can reach the owner at domains@astrazeneca.com but please make sure you have a good reason for unsolicited messages. Their country of residence is Sweden.
N/A
534
N/A
N/A
213.2K
3.4K
9.6K
53.4K
N/A
534